A Phase 1 interventional study of PA5108 in Open-angle Glaucoma, sponsored by PolyActiva Pty Ltd. Completed at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by PolyActiva Pty Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Glaucoma, Open-Angle with a site in Australia — none open to participants now, 2 under way, none of them phase 3. Glaucoma, Open-Angle · Australia.
Among the 14 studies in Glaucoma, Open-Angle with a site in Australia, this one is the 14th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 7th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 14 studies in Glaucoma, Open-Angle with a site in Australia is open now. The open studies under Glaucoma, Open-Angle, anywhere →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 5
First in 2002; this study’s year is marked. 2 started in 2018.
This study's enrollment of 8 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 14 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 9 most frequent:
PolyActiva Pty Ltd is the lead sponsor of 7 studies on the registry; none are open to participants now.
PolyActiva Pty Ltd has 5 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma, Open-Angle with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06964061PolyActiva Pty LtdEvaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Glaucoma, Open-Angle with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).
Participants who are currently managing their Open Angle Glaucoma with combination drop therapy will be recruited. Drop therapy will cease in the treatment eye and continue in the contralateral eye. The treated eye will receive via injection, a single PA5108 ocular implant. Participants will be monitored for safety and tolerability of the ocular implant until it completely biodegrades.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
Drug: PA5108
single ocular implant, administered on day 1
Safety and tolerability as measured by the occurrence of adverse events
Time frame: 4 weeks
Timeframe to complete implant biodegradation based on implant size and location
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Jun 2020, 22 months.
Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 22 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PA5108
PolyActiva Pty Ltd